MENU
+Compare
APLS
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$22.97
Change
+$0.29 (+1.28%)
Capitalization
2.89B

APLS Apellis Pharmaceuticals Forecast, Technical & Fundamental Analysis

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more

APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for APLS with price predictions
Apr 01, 2025

APLS's RSI Oscillator ascends from oversold territory

The RSI Indicator for APLS moved out of oversold territory on April 01, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In of the 23 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLS advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

APLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on APLS as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for APLS turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for APLS entered a downward trend on April 01, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.626) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (3.647) is also within normal values, averaging (251.391).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. APLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

APLS is expected to report earnings to rise 17.97% to -34 cents per share on May 01

Apellis Pharmaceuticals APLS Stock Earnings Reports
Q1'25
Est.
$-0.34
Q4'24
Beat
by $0.08
Q3'24
Missed
by $0.17
Q2'24
Beat
by $0.01
Q1'24
Missed
by $0.07
The last earnings report on February 28 showed earnings per share of -28 cents, beating the estimate of -37 cents. With 2.67M shares outstanding, the current market capitalization sits at 2.89B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
706
Web
https://www.apellis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEGFX55.200.40
+0.73%
American Funds Europacific Growth F1
RTDAX14.490.07
+0.49%
Russell Inv Multifactor US Equity A
DFVQX14.530.03
+0.21%
DFA International Vector Equity I
LMBMX12.17N/A
N/A
Franklin U.S. Small Cap Equity IS
PSMJX10.21N/A
N/A
Principal SmallCap Value II J

APLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NTLA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+3.70%
NTLA - APLS
41%
Loosely correlated
-6.40%
BEAM - APLS
40%
Loosely correlated
-9.70%
CRSP - APLS
40%
Loosely correlated
-2.62%
VERV - APLS
40%
Loosely correlated
-9.52%
DNLI - APLS
39%
Loosely correlated
-9.60%
More